We are proud to represent Oramed, a publicly traded company on Nasdaq and the Tel Aviv Stock Exchange and a long-standing client of the firm’s, in a significant transaction to establish a joint venture in the U.S. with the Chinese company HTIT.
This is a strategic move for Oramed that will advance the development and commercialization of its innovative oral insulin drug. Oramed will transfer its operations and intellectual property rights in the field of oral insulin to the joint venture. The deal involves a USD 15 million investment from Oramed and a USD 60 million from the Chinese partner. The deal is designed to accelerate the development and commercialization of oral insulin and other oral products based on Oramed’s POD™ technology.
A huge thank you to everyone involved with the transaction, especially Daniel Green, Micki Shapira, Michael Horowitz, Asaf Tenenbaum and Miriam Friedmann.
For more information, click here>>
